Gene polymorphism

Relationship between TBX20 gene polymorphism and congenital heart disease

X. F. Yang, Zhang, Y. F., Zhao, C. F., Liu, M. M., Si, J. P., Fang, Y. F., Xing, W. W., Wang, F. L., Yang, X. F., Zhang, Y. F., Zhao, C. F., Liu, M. M., Si, J. P., Fang, Y. F., Xing, W. W., and Wang, F. L., “Relationship between TBX20 gene polymorphism and congenital heart disease”, vol. 15, p. -, 2016.

Congenital heart disease in children is a type of birth defect. Previous studies have suggested that the transcription factor, TBX20, is involved in the occurrence and development of congenital heart disease in children; however, the specific regulatory mechanisms are yet to be evaluated. Hence, this study aimed to evaluate the relationship between the TBX20 polymorphism and the occurrence and development of congenital heart disease. The TBX20 gene sequence was obtained from the NCBI database and the polymorphic locus candidate was predicted.

Relationship between the G75A polymorphism in the apolipoprotein A1 (ApoA1) gene and the lipid regulatory effects of pravastatin in patients with hyperlipidemia

T. N. Liu, Wu, C. T., He, F., Yuan, W., Li, S. X., Li, H. W., Yu, H. Y., Wu, M., Liu, T. N., Wu, C. T., He, F., Yuan, W., Li, S. X., Li, H. W., Yu, H. Y., and Wu, M., “Relationship between the G75A polymorphism in the apolipoprotein A1 (ApoA1) gene and the lipid regulatory effects of pravastatin in patients with hyperlipidemia”, vol. 15, p. -, 2016.

In this study, we investigated the relationship between the G75A polymorphism in the apolipoprotein A1 (ApoA1) gene and the lipid regulatory effect of pravastatin in patients with hyperlipidemia. A total of 179 patients were divided into two groups: the pravastatin (N = 97) and policosanol (N = 82) treatment groups. The total cholesterol (TC), triglyceride, low-density lipoprotein (LDL-c), high-density lipoprotein, ApoA, and ApoB concentrations in the serum were measured using an automatic biochemical analyzer before and after treatment for 12 weeks.

Association of APOA1 gene polymorphisms (rs670, rs5069, and rs2070665) with dyslipidemia in the Kazakhs of Xinjiang

D. W. Feng, Ma, R. L., Guo, H., He, J., Yan, Y. Z., Muratbek,, Niu, Q., Li, S. G., Rui, D. S., Sun, F., Zhang, M., Zhang, J. Y., Ding, Y. S., Liu, J. M., Wang, K., Guo, S. X., Feng, D. W., Ma, R. L., Guo, H., He, J., Yan, Y. Z., Muratbek,, Niu, Q., Li, S. G., Rui, D. S., Sun, F., Zhang, M., Zhang, J. Y., Ding, Y. S., Liu, J. M., Wang, K., Guo, S. X., Feng, D. W., Ma, R. L., Guo, H., He, J., Yan, Y. Z., Muratbek,, Niu, Q., Li, S. G., Rui, D. S., Sun, F., Zhang, M., Zhang, J. Y., Ding, Y. S., Liu, J. M., Wang, K., and Guo, S. X., “Association of APOA1 gene polymorphisms (rs670, rs5069, and rs2070665) with dyslipidemia in the Kazakhs of Xinjiang”, vol. 15, p. -, 2016.

The aim of this study was to investigate the potential association between apolipoprotein A1 (APOA1) gene rs670, rs5069, and rs2070665 polymorphisms and dyslipidemia in the Kazakh population of Xinjiang, China. Matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF-MS) was used to identify APOA1 (rs670, rs5069, and rs2070665) genotypes in 736 subjects (341 dyslipidemia patients and 395 control subjects).

Subscribe to Gene polymorphism